Form D · Biotechnology
ProtaBody, Inc.
Pasadena, CA · CIK 0001867979
Offering snapshot reported Jun 16, 2021 · SEC filing
- Reported sold
- $800 Offering amount: $800
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $266 Reported outside-investor minimum
- First sale
- Jun 16, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 16, 2021 | Initial | $800 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 04, 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-403194
Source: Form D, filed Jun 16, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Paul Chang | Director, Executive |
| Justin Chartron | Director, Executive |
| Barry Olafson | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1010 Union Street Suite 110
Pasadena, CA, 91106
Pasadena, CA, 91106